drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous T cells engineered to express a CAR specific for CD20; upon CD20 engagement, CAR signaling activates T cells to eliminate CD20-positive B-cell malignancies and can result in on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD20-specific chimeric antigen receptor. Upon binding CD20, CAR signaling through CD3zeta and costimulatory domains activates and expands the T cells, leading to cytokine release and perforin/granzyme-mediated killing of CD20-positive B cells, resulting in depletion of malignant B cells and on-target B-cell aplasia.
drug_name
CD20-directed autologous CAR-T cells
nct_id_drug_ref
NCT06647329